Overview

• Biotech firm's Q4 net loss narrowed, beating analyst expectations

• Company maintains cash runway into Q1 2028

Outlook

• Dyne plans U.S. Accelerated Approval submission for z-rostudirsen in Q2 2026

• Company expects potential U.S. launch of z-rostudirsen in Q1 2027

• Dyne expects cash resources to fund operations into Q1 2028

Result Drivers

• HIGHER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses were $95.4 million and $81.8 million for the quarters ended December 31, 2025 and 2024, respectively

• HIGHER GENERAL AND ADMINISTRATIVE (G&A) EXPENSES: G&A expenses were $20.7 million and $15.3 million for the quarters ended December 31, 2025 and 2024, respectively.

Company press release: ID:nGNX8p6tVC

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS	Beat	-$0.76	-$0.77 (14 Analysts)
Q4 Net Income	Beat	-$111.96 mln	-$113.89 mln (12 Analysts)
Q4 Operating Income	Beat	-$116.13 mln	-$117.90 mln (12 Analysts)
Q4 Basic EPS		-$0.76
Q4 Operating Expenses		$116.13 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Dyne Therapeutics Inc is $40.00, about 156.1% above its February 27 closing price of $15.62

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.